Navigation Links
Morphine Painkillers Won't Impair Driving

Study found no difference in motorists' reaction times

SATURDAY, Oct. 13 (HealthDay News) -- Moderate, long-term use of opioid pain medications such as morphine does not impair a person's driving ability, U.S. researchers report.

A team at Rush University Medical Center in Chicago compared two groups of people -- 51 long-term users of oral morphine and 49 who weren't taking any pain medication. All the participants spent about 12 minutes in a driving simulator that measured deviation from the center of the road, weaving, number of accidents, and reaction time to unexpected events.

The average amount of weaving for both groups was 3.83 feet, and the morphine group had 5.33 collisions, compared with 5.04 collisions for the control group. Average reaction time for the morphine group was 0.67 seconds, compared with 0.69 seconds for the control group.

The findings suggest that patients who require long-term pain medication may "become tolerant" to side effects that could potentially impair function, said researcher Dr. Asokumar Buvanendran, an associate professor in the anesthesiology department at Rush.

The study was expected to be presented Oct. 13 at the annual meeting of the American Society of Anesthesiologists, in San Francisco.

Opioid pain relievers carry warning labels urging patients not to drive or operate heavy machinery while taking the medications, and drivers under the influence of pain drugs are typically subject to the same laws and penalties as people who drink and drive.

According to Buvanendran, this study's findings suggest that patients on long-term pain medication may be able to live "like normal functioning people, without the stigma and limitations now associated with long-term pain medication use."

More information

The American Academy of Family Physicians has more about chronic pain medicines.

-- Robert Preidt

SOURCE: American Society of Anesthesiologists, news release, Oct. 13, 2007

Copyright©2007 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Morphine may excite cancerous tumors
2. Morphine Withdrawal Complicates Hepatitis C Infection in Drug Abusers
3. Inhibition of morphine tolerance by spinal melanocortin receptor blockade
4. Using Morphine to Hasten Death Is a Myth, Says Doctor
5. How Morphine Affects Memory
6. Painkillers Do Not Shorten Dying Patients Lives
7. Drug dilemma confronts users of painkillers
8. Painkillers may protect against Alzheimers disease
9. Painkillers may raise miscarriage risk
10. Painkillers Increase Risk of Miscarriage
11. In The Habit Of Taking Painkillers For Your Chronic Headache? Time To Switch Over
Post Your Comments:
(Date:12/1/2015)... ... December 01, 2015 , ... ... continuing medical education (CME), today announced that the first annual School of Gastrointestinal ... , “The prevention, detection and treatment of gastrointestinal cancers are undergoing transformational change, ...
(Date:12/1/2015)... ... 01, 2015 , ... Speech and physical therapies are traditionally ... technologies and under the right circumstances, these practices can be merged. This ... to his or her therapeutic sessions, as well as gives the physical and ...
(Date:12/1/2015)... ... December 01, 2015 , ... CloudLIMS ... 2015 Golden Bridge Business Awards under the New Products and Services category for ... based sample management software that helps labs organize data and track ...
(Date:12/1/2015)... CHICAGO (PRWEB) , ... December 01, 2015 , ... ... risk quantification and optimization of adjunctive imaging is the focus of numerous abstracts ... (RSNA) meeting, November 29-December 4, 2015. Nine abstracts highlight the use of ...
(Date:12/1/2015)... ... 01, 2015 , ... SAN FRANCISCO, Calif. (December 1, 2015) ... has awarded Education and Developmental Therapies (EDT), an Applied Behavior Analysis (ABA) service ... special needs providers that excel in synthesizing the areas of clinical quality, staff ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... -- CytRx Corporation (NASDAQ: CYTR ), a biopharmaceutical ... that it has reached its enrollment target of 400 ... trial of aldoxorubicin in patients with previously treated soft ... in Q1 2016. The Phase 3 trial is a randomized, ... from the FDA at 79 sites in ...
(Date:12/1/2015)... Dec. 1, 2015  InCarda Therapeutics, Inc. (InCarda), a ... of therapies for cardiovascular conditions via the inhalation route, ... in Australia . InCarda is planning ... Australia in the first half of ... medical centers in Adelaide and ...
(Date:12/1/2015)... , Dec. 1, 2015  Booth #3506 – Claymount is ... the annual meeting of the Radiological Society of ... this year. Based in the Netherlands ... Varian Medical Systems (NYSE: VAR ) and is one ... chambers and solid state automatic exposure control systems for controlling ...
Breaking Medicine Technology: